Lactone stability and tissue distribution of free and liposomal encapsulated 9-nitrocamptothecin in rats following intravenous injection

Drug Development and Industrial Pharmacy

Volumn 34, Issue 8, 2008, Pages 853-859

  Chen, Jun ^a,b   Cai, Baochang ^a   Ping, Qineng ^b   Liu, Minling ^b   Guo, Jianxin ^c  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

^c UNIVERSITY OF KANSAS   (United States)

Author keywords

9 nitrocamptothecin; Lactone; Liposomes; Tissue distribution

Indexed keywords

LACTONE; LIPOSOME; RUBITECAN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG STABILITY; DRUG TISSUE LEVEL; ENCAPSULATION; IN VIVO STUDY; LIVER; MALE; NONHUMAN; RAT; RETICULOENDOTHELIAL SYSTEM; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; INJECTIONS, INTRAVENOUS; LACTONES; LIVER; MALE; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 49449092779     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040801928762     Document Type: Article

References (20)

1. Burke, T. G., & Mi, Z. (1994). The structural basis of camptothecin interactions with human serum albumin: Impact on drug stability. J. Med. Chem., 37, 40-46.
2. Cao, Z., Harris, N., Kozielski, A., Vardeman, D., Stehlin, J. S., & Giovanella, B. (1998). Alkyl esters of camptothecin and 9-nitrocamptothecin: Synthesis, in vitro pharmacokinetics, toxicity and antitumor activity. J. Med. Chem., 41, 31-37.
3. Chen, J., Ping, Q. N., Guo, J. X., Chu, X. Z., & Song, M. M. (2006a). Effect of phospholipid composition on characterization of liposomes containing 9-nitrocamptothecin. Drug Dev. Ind. Pharm., 32, 719-726.
4. Chen, J., Ping, Q. N., Guo, J. X., Chu, X. Z., & Song, M. M. (2006b). Pharmacokinetics of lactone, carboxylate and total 9-nitrocamptothecin with different doses and administration routes in rats. Biopharm. Drug Dispos., 27, 53-59.
5. Chen, J., Ping, Q. N., Guo, J. X., & Ding, M. G. (2005a). Effect of liposomes encapsulation on equilibrium between lactone and carboxylate forms of 9-nitrocamptothecin in vitro. J. China Pharm. Univ., 36, 316-320.
6. Chen, J., Ping, Q. N., Guo, J. X., Liu, L., Chu, X. Z., & Song, M. M. (2005b). In vitro and in vivo stability of 9-nitrocamptothecin lactone form in rats. Acta Pharmacol. Sin., 40, 888-892.
7. Chow, D. S., Gong, L., Wolfe, M. D., & Giovnella, B. C. (2000). Modified lactone/carboxylate salt equilibria in vivo by liposomal delivery of 9-nitrocamptothecin. Ann. N. Y. Acad. Sci., 922, 164-174.
8. Giovanella, B. C., Stehlin, J. S., Hinz, H. R., Kozielski, A. J., Harris, N. J., & Vardeman, D. M. (2002). Preclinical evaluation of the anticancer activity and toxicity of 9-nitro-20(s)-camptothecin (Rubitecan). Int. J. Oncol., 20, 81-88.
9. Hertzberg, R. P., Caranfa, M. J., Holden, K. G., Jakas, D. R., Gallagher, G., Mattern, M. R., Mong, S. M., Bartus, J. O., Johnson, R. K., & Kingsbury, W. D. (1989). Modification of the hydroxy lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity. J. Med. Chem., 32, 715-720.
10. Hung, C. L., Doniger, J., Palini, A., Snyder, S. W., Radonovich, M. F., Brady, J. N., Pantazis, P., & Sadaie, M. R. (2001). 9-Nitrocamptothecin inhibits HIV-1 replication in human periperal blood lymphocytes: A potential alternative for HIV-infection/AIDS therapy. J. Med. Virol., 64, 238-244.
11. Jiang, X. H. (2003). Drug excretion. In W. Q. Liang (Ed.), Biopharmaceutics and pharmacokinetics (2nd ed. p. 150). Beijing (China): People's Medical Publishing House.
12. Jung, L. L., Ramanathan, R. K., Egorin, M. J., Jin, R., Belani, C. P., Potter, D. M., Strychor, S., Trump, D. L., Walko, C., Fakih, M., & Zamboni, W. C. (2004). Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors. Cancer Chemother. Pharmacol., 54, 487-496.
13. Scott, D. O., Bindra, D. S., & Stella, V. J. (1993). Plasma pharmacokinetics of the lactone and carboxylate forms of 20(s)-camptothecin in anesthetized rats. Pharm. Res., 10, 1451-1457.
14. Sha, X., & Fang, X. (2004). Transport characteristics of 9-nitrocamptothecin in the human intestinal cell line Caco-2 and everted gut sacs. Int. J. Pharm., 272, 161-171.
15. Shenderova, A., Burke, T. G., & Schwendeman, S. P. (1997). Stabilization of 10-hydrocamptothecin in poly(lactide-co-glycolide) microsphere delivery vehicles. Pharm. Res., 14, 1406-1414.
16. Ulukan, H., & Swaan, P. W. (2002). Camptothecins: A review of their chemotherapeutic potential. Drugs, 62, 2039-2057.
17. Yang, S. C., & Zhu, J. B. (2002). Preparation and characterization of camptothecin solid lipid nanoparticles. Drug Dev. Ind. Pharm., 28, 265-274.
18. Zhang, R., Li, Y., Cai, Q., Liu, T., Sun, H., & Chambless, B. (1998). Preclinical pharmacology of the natural product anticancer agent 10-hydroxycamptothecin, an inhibitor of topoisomerase I. Cancer Chemother. Pharmacol., 41, 257-267.
19. Zhang, J. A., Xuan, T., Parmar, M., Ma, L., Ugwu, S., Ali, S., & Ahmad, I. (2004). Development and characterization of a novel liposome-based formulation of SN-38. Int. J. Pharm., 270, 93-107.
20. Zhong, D. F., Li, K., Xu, J. H., Yue, D., & Fan, Y. F. (2003). Pharmacokinetics of 9-nitro-20(s)-camptothecin in rats. Acta Pharmacol. Sin., 24, 256-262.